Close
  Indian J Med Microbiol
 

Figure 1: (a) Increase serotonin at the somatodendritic and terminal presynaptic region, which as a result of SSRI or SNRI or NASSA pharmacodynamics effect activates the 5-HT1A and 5-HT1B autoreceptors, thereby leading to a decrease in serotonin release in the terminal presynaptic region and firing rate in the somatodendritic region and thus reduced antidepressant and anti-anxiety clinical responses. (b) The addition of a drug such as a selective 5-HT1A autoreceptor partial agonist (buspirone) or 5-HT1A and 5-HT1B autoreceptors antagonist (pindolol) can hasten antidepressant and anti-anxiety clinical responses to SSRI or SNRI or NASSA

Figure 1: (a) Increase serotonin at the somatodendritic and terminal presynaptic region, which as a result of SSRI or SNRI or NASSA pharmacodynamics effect activates the 5-HT<Subscript>1A</Subscript> and 5-HT<Subscript>1B</Subscript> autoreceptors, thereby leading to a decrease in serotonin release in the terminal presynaptic region and firing rate in the somatodendritic region and thus reduced antidepressant and anti-anxiety clinical responses. (b) The addition of a drug such as a selective 5-HT<Subscript>1A</Subscript> autoreceptor partial agonist (buspirone) or 5-HT<Subscript>1A</Subscript> and 5-HT<Subscript>1B</Subscript> autoreceptors antagonist (pindolol) can hasten antidepressant and anti-anxiety clinical responses to SSRI or SNRI or NASSA